Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 7146
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sorensen, J. B. Articles by Aaseboe, U. Search for Related Content PubMed Articles by Sorensen, J. B. Articles by Aaseboe, U.

Abstract

Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3

National Univ Hosp, Copenhagen, Denmark; Univ Hosp, Helsinki, Finland; Odense Univ Hosp, Odense, Denmark; Aarhus Kommunehospital, Aarhus, Denmark; Vejle Hosp, Vejle, Denmark; Aarhus Kommunehospital, Aarhus, Denmark; Tromsoe Hosp, Tromsoe, Norway

7146

Background: Neoadjuvant chemotherapy before surgery for NSCLC has previously shown somewhat promising results, but all prior randomised studies included also patients (pts) with N2-disease or stage IIIB. The aim was thus to evaluate the impact of neoadjuvant chemotherapy for early stage disease (stages IB - IIIA/T3). Methods: Pts had histologically verified NSCLC stages IB, IIA, IIB, and IIIA/T3 based on CT-scan and negative mediastinoscopy, and were randomised to 3 courses of Paclitaxel 225 mg/m² and Carboplatin AUC 6 day 1 q 3 weeks followed by surgery (regimen A) or immidiate surgery (regimen B). Chest radiotherapy 60 Gy were administered in case of incomplete resection. Survival was primary end-point. It was required to randomise totally 280 pts to detect an 15% increment in 5-year survival rate with a two-sided type I error of 5% and 80% power. The study was stopped prematurely due to slow patient recruitment. Results: 44 pts with a median age of 66 years were randomised to regimen A and 46 with median age 62 years to regimen B from November 1998 to October 2004. There were no differences with respect to performance status, gender, histology, LDH, or stage groups between the treatment regimens. In regimen A, 46% achieved a partial response to the neoadjuvant chemotherapy. Microscopically complete resection was achieved in 79% and 70% in regimen A and B, respectively. Median survival and 5-year survival rates were 34.4 months and 36% compared to 22.5 months and 24% in regimen A and B, respectively (not significant). Conclusions: No statistically significant differences were noted in this prematurely closed trial, but median survival was increased by one year and 5-year survival rate increased by 12% for pts receiving neoadjuvant chemotherapy, suggesting that a beneficial effect can not be ruled out. Follow-up and survival update continues.

No significant financial relationships to disclose.

Abstract presentation from the 2005 ASCO Annual Meeting